Table 1 Patient Group and Clinical Data
No. | Age | Sex | Tumor location | Tumor stagea | Lymph node metastasesa | Hematogenous metastasesb | Tumor recurrence | Interval (months)c |
|---|---|---|---|---|---|---|---|---|
1 | 85 | F | G+ | pT4 | pN0 | M0 | + | 24 |
2 | 50 | M | Supra-G | pT4 | pN1 | M0 | + | 12 |
3 | 56 | M | G | pT4 | pN2c | M1 | − | — |
4 | 58 | M | G | pT4 | pN0 | M1 | − | — |
5 | 59 | F | Supra-G | pT3 | pN2b | M0 | − | — |
6 | 50 | M | G | pT3 | pN0 | M0 | − | — |
7 | 86 | M | E+ | pT2 | pN0 | M0 | + | 6 |
8 | 71 | M | E | pT3 | pN0 | M0 | − | — |
9 | 62 | M | Sub-G | pT4 | pN0 | M0 | − | — |
10 | 54 | M | Supra-G | pT4 | pN2b | M1 | + | 10 |
11 | 66 | M | G | pT4 | pN2b | M0 | + | 5 |
12 | 53 | M | G | pT3 | pN0 | M0 | − | — |
